Back to search

University of British Columbia

The role of gut microbiota in Parkinson's disease

Abstract

dc:description

Parkinson’s disease (PD) is a neurodegenerative disorder characterized by motor dysfunction. Non-motor symptoms including gastrointestinal (GI) dysfunction and mood disorders (such as depression) are also particularly common. GI symptoms include constipation, and PD patients display altered gut microbiota composition. Evidence in animal models points towards a potential causal role for the microbiota in mediating PD pathology. However, the constipation, medication use, and lifestyle habits of PD patients can also be expected to change microbiota composition. In this thesis, I explore the role of the gut microbiota in PD, in terms of the degree that it is shaped by the disease state and its ability to mediate disease symptoms. Using a transgenic mouse model of PD that displays motor deficits, GI dysfunction, and behavioral alterations, I assessed how broad alterations to the gut microbiota impacted the motor and non-motor phenotype. I found that both depletion of the microbiota through antibiotics, and a shift towards a healthy wild-type mouse microbiota, had a minimal impact on the PD-like symptoms. This suggested that the PD-like transgenic state of this model may drive the disease phenotype to a greater extent than the microbiota. Similarly, I demonstrated that the decreased abundance of Lachnospiraceae and decreased abundance of Ruminococcaceae and Oscillospira observed in PD patients may be a result of constipation by treating PD mice with laxatives that reversed these shifts. Lachnospiraceae abundance was also found to be decreased by treatment of this model with the PD medications L-DOPA and carbidopa. Conversely, different antibiotic treatment regimens were able to shift the microbial community and alter GI transit time in PD mice. Specific bacterial taxa, such as Lachnospiraceae (Ruminococcus), were associated with transit time – indicating a potential to treat PD constipation via the microbiota. Furthermore, treatment of PD mice with PD medications had a beneficial effect on constipation and depression-like behavior, potentially through increasing the abundance of Turicibacter and promoting butyrate production. This thesis demonstrates that certain PD-associated microbiota alterations may be a result of slowed GI transit or the presence of medications. However, specific shifts to the gut microbiota may in turn mediate non-motor symptoms in PD.

Degree

thesis:*
Name thesis:degree_name
Doctor of Philosophy - PhD
Level thesis:degree_level
doctoral
Discipline thesis:degree_discipline
Biochemistry and Molecular Biology
Grantor dc:publisher
University of British Columbia
Year dc:date
2023

Author and committee

dc:creator, dc:contributor.*
Author dc:creator
  • Radisavljevic, Nina
Contributors dc:contributor
  • Finlay, B. Brett

Rights

dc:rights
Statement dc:rights
  • Attribution-NonCommercial-NoDerivatives 4.0 International
Language dc:language
eng

Identifiers

dc:identifier.*
Handle dc:identifier
http://hdl.handle.net/2429/85966

Chain of custody

source
Harvested from
University of British Columbia
Base URL
circle.library.ubc.ca/oai/request
Last updated
2026-11-19
Source record
OAI-PMH GetRecord
related terms
citation

Radisavljevic, Nina. The role of gut microbiota in Parkinson's disease. doctoral thesis, University of British Columbia, 2023. http://hdl.handle.net/2429/85966